Physician profile
Doreen Blake
NPI 1043209331
$9,218.78
in general payments reported to CMS, 2019-2025
29 companies · $2,101 in 2025
The $2,101 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $954 · 2020: $416 · 2021: $995 · 2022: $1,631 · 2023: $2,038 · 2024: $1,083 · 2025: $2,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,222.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,055.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,542.64 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $999.51 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $749.70 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $742.11 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $518.18 | 2019-2025 | |
| Amgen INC. | $432.09 | 2023-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $309.10 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Vanda Pharmaceuticals INC. | $268.68 | 2019-2023 | Hetlioz, Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.39 | 2019-2025 | Jardiance, Tradjenta |
| Sanofi-Aventis U.S. LLC | $216.74 | 2021-2023 | |
| Abbott Laboratories | $187.85 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $186.00 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $150.61 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $93.95 | 2023-2024 | Quviviq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $89.69 | 2022 | |
| Dexcom, INC. | $80.08 | 2024-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $66.88 | 2022-2024 | |
| Astellas Pharma US INC | $66.21 | 2025 | Veozah |
| Corcept Therapeutics | $47.33 | 2025 | Korlym |
| Allergan, INC. | $42.67 | 2019-2020 | |
| Dynavax Technologies Corporation | $27.66 | 2025 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $18.51 | 2021 | |
| Seqirus USA INC | $18.49 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Horizon Therapeutics Plc | $17.11 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.14 | 2021 | |
| Paratek Pharmaceuticals, INC. | $14.74 | 2025 | Nuzyra |
| Arbor Pharmaceuticals, INC. | $11.93 | 2022 | |
| Eisai INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doreen Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.